Another study demonstrated that the serial killing potential and in vivo anti-tumor response through both native or transgenic TCR was increased by co-expression of CD19 CARs with 4-1BB co-stimulation but lacking the CD3ζ signaling domain [207]. Here, TNFRSF9 is linked to neoplasm.